AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, rising 4.2% year over year ...

AbbVie has announced that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, ...

Earnings of $2.97 per share rose 12.1% year over year. Revenues of $15.42 billion rose 6.6% year over year on a reported basis, driven by robust sales of key drugs like Rinvoq, Skyrizi, Venclexta and ...

FDA endorses bexmarilimab for higher-risk myelodysplastic syndromes, paving the way for accelerated approval and promising ...

Olutasidenib could dramatically extend survival and reduce dependence on transfusions for certain patients with myelodysplastic syndrome, according to results of a phase 1/2 investigation.Individuals ...

For BMS, the data positions CC-486 into a segment of the AML market that for the time being sidesteps competition from Venclexta and other drugs coming through the pipeline like Roche’s MDM2 ...

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating ...

AstraZeneca received approval from the Japanese regulator following a priority review of Tagrisso (osimertinib) as a first-line treatment of patients with positive non-small cell lung cancer ...

AbbVie’s stock jumped 11.5% this past month, following a strong quarterly performance. The company reported $15.42 billion in revenue, marking a 6.6% increase year over year. Key products like Rinvoq ...